Meeting Spolight: 2021 International Kidney Cancer Symposium
Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.
Despite advanced in the field of renal cell carcinoma, most patients still die of the disease and more options and new targets are needed, says Moshe C. Ornstein, MD, MA.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
2
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
3
NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer
4
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer
5